美好醫療系統 MMSI 深 滬
等待開盤 01-29 09:30:00 美东时间
80.50
-1.900
-2.31%
華盛通- 最 高82.36
- 今 開82.28
- 成交量 92.88万股
- 最 低 80.18
- 昨 收 82.40
- 總市值 47.67亿
- 52周最高 110.67
- 市盈率 靜 39.71
- 換手率 1.57%
- 52周最低 78.116
- 委 比 -69.74%
- 總股本 5921.91万
- 歷史最高 111.45
- 量 比 1.85
- 振 幅 2.65%
- 歷史最低 9.15
- 每 手 1
- 風險率 7.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Merit Medical Systems Appoints F. Ann Millner Board Chair, Effective Jan. 5, Succeeding Fred P. Lampropoulos; Reports Q4 Preliminary Revenue ~$389M To $395M
Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that its Board of Directors unanimously appointed F. Ann Millner, Ed.D., formerly Merit's Lead Independent Director,
01-09 05:08
Merit Medical Appoints F. Ann Millner as Chair of the Board and Announces Projected Preliminary Unaudited Revenue Results for the Fourth Quarter of 2025
Merit Medical Systems announced F. Ann Millner, Ed.D., as its new Board Chair, succeeding Fred P. Lampropoulos, who resigned after 38 years at the company. Fourth-quarter 2025 revenue is projected to increase 10-11% year-over-year. A conference call will discuss financial results on February 24, 2026.
01-08 21:05
Merit Medical to Participate at the J.P. Morgan Healthcare Conference
Merit Medical Systems, Inc. announced that its management will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026. Martha G. Aronson, CEO, and Raul Parra, CFO, will present a company overview on January 13 at 4:30 PM PT / 7:30 PM ET. Presentation materials and a live audio webcast will be available on Merit’s investor relations website, with a replay accessible for 90 days.
2025-12-23 14:00
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
Is the Market Bullish or Bearish on Merit Medical Systems Inc?
Merit Medical Systems Inc's (NYSE:MMSI) short interest as a percent of float ha...
2025-12-12 21:00
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
Barrington Research Maintains Outperform on Merit Medical Systems, Maintains $106 Price Target
Barrington Research analyst Michael Petusky maintains Merit Medical Systems (NASDAQ:MMSI) with a Outperform and maintains $106 price target.
2025-11-15 04:29
Merit Medical Systems Begins WRAPSODY CIE Commercialization
An announcement from Merit Medical Systems ( ($MMSI) ) is now available. Merit ...
2025-11-14 06:51
Merit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY® Cell-Impermeable Endoprosthesis
Merit Medical Systems announced that the U.S. CMS has deferred its application for transitional pass-through incremental payment for WRAPSODY® CIE procedures until 2027. CEO Martha Aronson stated that while disappointed, this presents an opportunity for a strategic pivot, focusing on patient access, adoption, and utilization of their technology. WRAPSODY® CIE received FDA and Health Canada approval in 2024 and 2025, respectively, and is available...
2025-11-13 21:05
